{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:43:41Z","timestamp":1790613821696,"version":"4.1.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA048063"],"award-info":[{"award-number":["R01DA048063"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["K24DA034621"],"award-info":[{"award-number":["K24DA034621"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The design of a clinical trial for a controlled human infection model (CHIM) to accelerate hepatitis C virus (HCV) vaccine development requires careful consideration. The design of a potential approach to HCV CHIM is outlined, involving initial sentinel cohorts to establish the safety and curability of the viral inoculum followed by larger cohorts to establish the spontaneous clearance rate for each inoculum. The primary endpoint would be HCV clearance by 24 weeks post-inoculation, recognizing that the prevention of chronic infection would be the primary goal of HCV vaccine candidates. Additional considerations are discussed, including the populations to be enrolled, the required monitoring approach, indications for antiviral therapy, and the required sample size for different CHIM approaches. Finally, safety considerations for CHIM participants are discussed.<\/jats:p>","DOI":"10.1093\/cid\/ciad362","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:26:10Z","timestamp":1692037570000},"page":"S262-S269","source":"Crossref","is-referenced-by-count":12,"title":["Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2211","authenticated-orcid":false,"given":"Jordan J","family":"Feld","sequence":"first","affiliation":[{"name":"Toronto Centre for Liver Disease, University Health Network, University of Toronto , Toronto , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bruneau","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CRCHUM), Universit\u00e9 de Montr\u00e9al , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J","family":"Dore","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales , Sydney , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G","family":"Ghany","sequence":"additional","affiliation":[{"name":"Liver Diseases Branch, National Institutes of Diabetes, Digestive, and Kidney Diseases , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Erasmus University , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sulkowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Johns Hopkins University , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Johns Hopkins University , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"key":"2023081418260070700_ciad362-B1","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1093\/cid\/ciaa640","article-title":"Ethical and practical issues associated with the possibility of using controlled human infection trials in developing a hepatitis C virus vaccine","volume":"71","author":"Cox","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023081418260070700_ciad362-B2","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","article-title":"Protection against persistence of hepatitis C","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"},{"key":"2023081418260070700_ciad362-B3","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMsb2109093","article-title":"Controlled human infection model\u2014fast track to HCV vaccine?","volume":"385","author":"Liang","year":"2021","journal-title":"N Engl J Med"},{"key":"2023081418260070700_ciad362-B4","article-title":"Challenge inoculum for hepatitis C virus controlled human infection model","volume":"77","author":"Liang","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023081418260070700_ciad362-B5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","author":"Osburn","year":"2010","journal-title":"Gastroenterology"},{"key":"2023081418260070700_ciad362-B6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022476","article-title":"Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study","volume":"6","author":"Omland","year":"2011","journal-title":"PLoS One"},{"key":"2023081418260070700_ciad362-B7","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.510290311","article-title":"Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection","volume":"29","author":"Villano","year":"1999","journal-title":"Hepatology"},{"key":"2023081418260070700_ciad362-B8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/428578","article-title":"Prospective evaluation of community-acquired acute-phase hepatitis C virus infection","volume":"40","author":"Cox","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023081418260070700_ciad362-B9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122232","article-title":"Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study","volume":"10","author":"Hajarizadeh","year":"2015","journal-title":"PLoS One"},{"key":"2023081418260070700_ciad362-B10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of a vaccine regimen to prevent chronic HCV infection","volume":"384","author":"Page","year":"2021","journal-title":"N Engl J Med"},{"key":"2023081418260070700_ciad362-B11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis C virus infection: host, viral, and environmental factors","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"key":"2023081418260070700_ciad362-B12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"2023081418260070700_ciad362-B13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat Genet"},{"key":"2023081418260070700_ciad362-B14","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1086\/605947","article-title":"Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection","volume":"200","author":"Page","year":"2009","journal-title":"J Infect Dis"},{"key":"2023081418260070700_ciad362-B15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.26639","article-title":"The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection","volume":"59","author":"Grebely","year":"2014","journal-title":"Hepatology"},{"key":"2023081418260070700_ciad362-B16","year":"1979"},{"key":"2023081418260070700_ciad362-B17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023081418260070700_ciad362-B18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1089\/08892220050042846","article-title":"A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group","volume":"16","author":"McElrath","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023081418260070700_ciad362-B19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1473-3099(07)70237-2","article-title":"Vaccine immunogenicity in injecting drug users: a systematic review","volume":"7","author":"Baral","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"1\u20133","key":"2023081418260070700_ciad362-B20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drugalcdep.2011.10.009","article-title":"Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs","volume":"123","author":"Park","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"2023081418260070700_ciad362-B21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jsat.2019.03.010","article-title":"Willingness to participate in hepatitis C vaccine trials among socially marginalized people who use drugs","volume":"101","author":"Yakovenko","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"2023081418260070700_ciad362-B22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cct.2014.12.015","article-title":"Hepatitis C vaccine clinical trials among people who use drugs: potential for participation and involvement in recruitment","volume":"41","author":"Young","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"2023081418260070700_ciad362-B23","article-title":"COVID-19 vaccination acceptability and experiences among people who inject drugs in San Diego County","volume":"30","author":"Valasek","year":"2022","journal-title":"Prev Med Rep"},{"key":"2023081418260070700_ciad362-B24","doi-asserted-by":"crossref","DOI":"10.2196\/35066","article-title":"How vaccine ambivalence can lead people who inject drugs to decline COVID-19 vaccination and ways this can be addressed: qualitative study","volume":"6","author":"Aronson","year":"2022","journal-title":"JMIR Form Res"},{"key":"2023081418260070700_ciad362-B25","year":"2000"},{"key":"2023081418260070700_ciad362-B26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1001\/journalofethics.2017.18.1.fred1-1601","article-title":"\u201cNothing about US without US\u201d: toward patient- and family-centered care","volume":"18","author":"Paul","year":"2016","journal-title":"AMA J Ethics"},{"key":"2023081418260070700_ciad362-B27","article-title":"Nothing about US without US\u201d\u2014greater, meaningful involvement of people who use illegal drugs: a public health, ethical, and human rights imperative, international edition. Canadian HIV\/AIDS Legal Network, International HIV\/AIDS Alliance","author":"J\u00fcrgens","year":"2008","journal-title":"Open Society Institute"},{"key":"2023081418260070700_ciad362-B28","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.1016\/j.vaccine.2010.08.085","article-title":"Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities","volume":"28","author":"Maher","year":"2010","journal-title":"Vaccine"},{"key":"2023081418260070700_ciad362-B29","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/JIM.0000000000000097","article-title":"Why we need community engagement in medical research","volume":"62","author":"Holzer","year":"2014","journal-title":"J Investig Med"},{"key":"2023081418260070700_ciad362-B30","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/aje\/kwn237","article-title":"Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place","volume":"168","author":"Hagan","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2023081418260070700_ciad362-B31","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jvh.12866","article-title":"Assessing hepatitis C spontaneous clearance and understanding associated factors\u2014a systematic review and meta-analysis","volume":"25","author":"Aisyah","year":"2018","journal-title":"J Viral Hepat"},{"key":"2023081418260070700_ciad362-B32","first-page":"ciad359","article-title":"Immunological monitoring in hepatitis C virus controlled human infection model","author":"Shoukry","year":"2023","journal-title":"Clinical Infectious Diseases"},{"key":"2023081418260070700_ciad362-B33","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"2023081418260070700_ciad362-B34","first-page":"3","article-title":"The utility of human challenge studies in vaccine development: lessons learned from cholera","volume":"1","author":"Shirley","year":"2011","journal-title":"Vaccine (Auckl)"},{"key":"2023081418260070700_ciad362-B35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12916-015-0440-2","article-title":"The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments","volume":"13","author":"Scott","year":"2015","journal-title":"BMC Med"},{"key":"2023081418260070700_ciad362-B36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.5858\/2007-131-702-CROTAA","article-title":"Current risks of transfusion-transmitted agents: a review","volume":"131","author":"Stramer","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"2023081418260070700_ciad362-B37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"2023081418260070700_ciad362-B38","first-page":"1141","article-title":"Acute hepatitis C infection with prolonged intrahepatic cholestasis and remarkable progression of fibrosis mimicking fibrosing cholestatic hepatitis","volume":"111","author":"Akagi","year":"2014","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"2023081418260070700_ciad362-B39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-2600(19)30268-1","article-title":"Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial","volume":"8","author":"Cypel","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2023081418260070700_ciad362-B40","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.2169\/internalmedicine.2982-19","article-title":"Ledipasvir and sofosbuvir for acute hepatitis C virus monoinfection associated with a high risk of acute liver failure","volume":"58","author":"Hatanaka","year":"2019","journal-title":"Intern Med"},{"key":"2023081418260070700_ciad362-B41","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jhep.2019.01.031","article-title":"Retreatment of patients who failed glecaprevir\/pibrentasvir treatment for hepatitis C virus infection","volume":"70","author":"Wyles","year":"2019","journal-title":"J Hepatol"},{"key":"2023081418260070700_ciad362-B42","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.14309\/ajg.0000000000000248","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for previous treatment failures with glecaprevir\/pibrentasvir in chronic hepatitis C infection","volume":"114","author":"Pearlman","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2023081418260070700_ciad362-B43","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad344","article-title":"Direct-acting antiviral therapy for treatment of acute and recent hepatitis C virus infection: a narrative review","volume":"77","author":"Martinello","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023081418260070700_ciad362-B44","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and lung transplants from HCV-infected donors to uninfected recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N Engl J Med"},{"key":"2023081418260070700_ciad362-B45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","article-title":"Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study","volume":"5","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023081418260070700_ciad362-B46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.31011","article-title":"HCV NAT positive solid organ allografts transplanted into HCV negative recipients: a real-world experience","volume":"72","author":"Kapila","year":"2020","journal-title":"Hepatology"},{"key":"2023081418260070700_ciad362-B47","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad380","article-title":"Risk of hepatocellular carcinoma after spontaneous clearance of hepatitis C virus and in noncirrhosis chronic hepatitis C patients with sustained virological response: a systematic review","volume":"77","author":"Hsu","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023081418260070700_ciad362-B48","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/hep.22802","article-title":"Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro","volume":"49","author":"MacParland","year":"2009","journal-title":"Hepatology"},{"key":"2023081418260070700_ciad362-B49","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1172\/JCI73104","article-title":"Trace amounts of sporadically reappearing HCV RNA can cause infection","volume":"124","author":"Veerapu","year":"2014","journal-title":"J Clin Invest"},{"key":"2023081418260070700_ciad362-B50","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/hep.32632","article-title":"Implementation of a controlled human infection model for evaluation of HCV vaccine candidates","volume":"77","author":"Barnes","year":"2022","journal-title":"Hepatology"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_3\/S262\/51111417\/ciad362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_3\/S262\/51111417\/ciad362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:26:29Z","timestamp":1692037589000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/Supplement_3\/S262\/7242435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":50,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2023,8,14]]},"published-print":{"date-parts":[[2023,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad362","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,15]]},"published":{"date-parts":[[2023,8,14]]}}}